Ignite Creation Date:
2024-05-06 @ 2:12 PM
Last Modification Date:
2024-10-26 @ 1:27 PM
Study NCT ID:
NCT04248387
Status:
UNKNOWN
Last Update Posted:
2020-01-30
First Post:
2020-01-28
Brief Title:
Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
A Clinical Study on the Efficacy and Safety of Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Resectable Stage III IV Malignant Melanoma
Status:
UNKNOWN
Status Verified Date:
2020-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FU-Name-T001
Brief Summary:
In view of the fact that neoadjuvant therapy for malignant melanoma is in the exploratory stage and the current data on neoadjuvant immunology are mainly from European and American populations it is necessary to carry out clinical trials in the status of neoadjuvant immunotherapy for patients with melanoma in China Toripalimab has been extensively studied in the field of malignant melanoma and its effectiveness and safety have been proven Therefore the investigators initiated a single-arm exploratory study to investigate the efficacy and safety of Toripalimab in neoadjuvant treatment of patients with BRAF V600 wild-type malignant melanoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None